Clobetasol Propionate Gel Recalled Due to Manufacturing Deviations
Teligent Pharma is recalling all unexpired batches of Clobetasol Propionate Gel 0.05% due to deviations from good manufacturing practices. The firm discontinued its stability study program, prompting the recall of 81,883 tubes distributed nationwide and in Puerto Rico.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall. The source text indicates a cGMP deviation (discontinuation of stability studies) rather than confirmed product contamination, manufacturing defect, or reported patient harm. The recall is precautionary in nature based on manufacturing practice deviations, without evidence of adverse events.
Plain-English summary
Teligent Pharma, Inc. is recalling Clobetasol Propionate Gel 0.05% in three package sizes: 15-gram tubes (NDC 52565-082-15), 30-gram tubes (NDC 52565-082-30), and 60-gram tubes (NDC 52565-082-60). A total of 81,883 tubes are affected.
The recall was initiated because the firm is discontinuing its stability study program, which constitutes a deviation from current good manufacturing practice (cGMP) requirements. All products within their expiration dates are included in the recall.
The affected product has been distributed nationwide in the United States and in Puerto Rico. Specific batch numbers and expiration dates are listed in the agency documentation.
Patients who have been prescribed this medication should contact their healthcare provider or pharmacist for guidance on alternative treatments or verification of whether their specific batch is affected.
The recalled product
- Product
- Clobetasol Propionate Gel, 0.05%, packaged in a) 15 grams tube, NDC 52565-082-15; b) 30 grams tube, NDC 52565-082-30; c) 60 grams tube, NDC 52565-082-60, Rx Only, Teligent Pharma, Inc., Buena, NJ 08310.
- Manufacturer
- Teligent Pharma, Inc.
- Category
- Drug — Topical Corticosteroid
- Hazard
- cGMP-deviation
- stability-study-discontinuation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Batch: a) 15063
- Exp. 2/28/2022
- 15928
- Exp. 9/30/2022
- 16432
- Exp. 2/28/2023
- 16769
- Exp. 4/30/2023
- b) 15243
- 16628
- Exp. 3/31/2023
- c) 15064
- 15286
- 15287
- 16173
- Exp. 11/30/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27